JP2024500946A5 - - Google Patents

Info

Publication number
JP2024500946A5
JP2024500946A5 JP2023538767A JP2023538767A JP2024500946A5 JP 2024500946 A5 JP2024500946 A5 JP 2024500946A5 JP 2023538767 A JP2023538767 A JP 2023538767A JP 2023538767 A JP2023538767 A JP 2023538767A JP 2024500946 A5 JP2024500946 A5 JP 2024500946A5
Authority
JP
Japan
Prior art keywords
nanobody
antigen
binding fragment
thrombosis
gpvi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500946A (ja
Filing date
Publication date
Priority claimed from GBGB2020602.5A external-priority patent/GB202020602D0/en
Application filed filed Critical
Publication of JP2024500946A publication Critical patent/JP2024500946A/ja
Publication of JP2024500946A5 publication Critical patent/JP2024500946A5/ja
Pending legal-status Critical Current

Links

JP2023538767A 2020-12-24 2021-12-21 糖タンパク質viに対するナノボディ Pending JP2024500946A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody
GB2020602.5 2020-12-24
PCT/EP2021/087129 WO2022136457A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi

Publications (2)

Publication Number Publication Date
JP2024500946A JP2024500946A (ja) 2024-01-10
JP2024500946A5 true JP2024500946A5 (cg-RX-API-DMAC7.html) 2024-11-06

Family

ID=74532190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538767A Pending JP2024500946A (ja) 2020-12-24 2021-12-21 糖タンパク質viに対するナノボディ

Country Status (7)

Country Link
US (1) US20240067721A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500946A (cg-RX-API-DMAC7.html)
CN (1) CN117043191A (cg-RX-API-DMAC7.html)
CA (1) CA3203202A1 (cg-RX-API-DMAC7.html)
GB (1) GB202020602D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022136457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
WO2007091719A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 抗gpvi抗体の併用療法及び新規医薬用途
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Similar Documents

Publication Publication Date Title
Xu et al. Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis
Hohmann et al. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
JP6033781B2 (ja) 低分子ペプチド阻害剤によるCD40L/Mac−1相互作用の選択的ターゲティングならびに炎症およびアテローム形成の治療のためのその使用
CA2916399C (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
Navarro et al. The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice
US9365650B2 (en) Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa
JP2005510719A (ja) 新規自己集合分子
NZ540771A (en) Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
TWI786485B (zh) 抗血小板膜糖蛋白ib alpha人源化抗體及其應用
US20210179717A1 (en) Antibodies against mac-1
AU2002352438B2 (en) Human antibodies against human glycoprotein VI and their use
US20110045008A1 (en) Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
TW201728603A (zh) 凝血酶抗體、其抗原結合片段及醫藥用途
JP7839117B2 (ja) 抗プロテインsシングルドメイン抗体及びそれを含むポリペプチド
Qian et al. Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library
JP2024500946A (ja) 糖タンパク質viに対するナノボディ
UA64693C2 (en) Novel staphylokinase derivatives, a method for the preparation thereof and pharmaceutical composition
Maurice et al. Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse
US20090311267A1 (en) Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks
CN109157654B (zh) Tmx1的用途
WO2020243228A1 (en) Antibodies to polyphosphate decrease fibrosis
US20250051452A1 (en) Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
Zhu et al. Generation and characterization of a recombinant single chain Fv antibody to von Willebrand factor A1 domain from phage display library
JP2026509897A (ja) 抗gpvi抗体及びその機能的断片
Lee et al. Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy